Summary
50 / 100 · Bulios Score
What speaks for it
- Out of every 100 USD of revenue, 24 USD is left as net profit.
- It holds more cash than debt: $373.6M against $19.2M.
- Analysts expect revenue to grow by 30% this fiscal year.
What to watch
- The share price is above the Bulios Fair Price.
- Revenue growth is slowing: 5.7% a year over the last 3 years against 15% over 5 years.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 31.3 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
SlowlyRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 15% a year over 5 years. Over the last 3 years it grew by 5.7% a year. For the next fiscal year analysts expect revenue to grow by 30%.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 29 USD
- Research and development 17 USD
- Sales and administration 54 USD
- Taxes and other -25 USD
- Net profit 24 USD
Net profit, industry median (Medical - Diagnostics & Research) 8.8 USD
Out of every 100 USD of revenue, 24 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesIt could repay all its debt from a single year of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 10
- Hold 3
- Sell 0
Today's price within the analysts' price targets
The average target of $62.25 is 7.2% below today's price. 77% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Service 85%
- Product 15%
By region
- UNITED STATES 95%
- Non-US 5.2%
Service brings in 85% of revenue.
Segments in detail